Mark Krul

Mark Krul, Ph.D., is co-founder of Aglaia Biomedical Ventures, a venturing firm in the field of oncology. He has a background in molecular biology and immunology and can rely on more than 12 years experience in anticancer drug development. He held several positions at NDDO Oncology BV, was research manager of the European Cancer Center and head of the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection (The Netherlands).

Karl Rothweiler, CFO

Before co-founding Aglaia Biomedical Ventures, Karl Rothweiler was involved in the founding, restructuring and funding of multiple technology driven companies. After completing his studies at The Netherlands School of Business Nijenrode, he received his MBA from the University of Georgia (USA).